EP4093418A1 - Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associé - Google Patents
Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associéInfo
- Publication number
- EP4093418A1 EP4093418A1 EP21701269.9A EP21701269A EP4093418A1 EP 4093418 A1 EP4093418 A1 EP 4093418A1 EP 21701269 A EP21701269 A EP 21701269A EP 4093418 A1 EP4093418 A1 EP 4093418A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition according
- officinalis
- glechoma
- ivy
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- the present invention relates to a composition in a form suitable for topical herbal administration, as well as its method of manufacture.
- the invention also relates to such a composition for its use in the treatment or prevention of symptoms in the event of dermatological or gasfroenferological conditions, in particular of procfological conditions such as hemorrhoidal disease.
- Hemorrhoids are normal vascular formations located around e ⁇ inside the anus e ⁇ of the rectum, which are present in all individuals and are painless. Internal hemorrhoids are ⁇ located inside the anal canal under the lining of the intestinal lining. It is a question of a system of organization of the vessels which is particularly complex: it comprises venous sacs covered with arterioles, therefore the blood content can vary very quickly. The volume of hemorrhoidal packets contributes 10 to 20% to anal tightness. External hemorrhoids are ⁇ located under the skin rim of the anus (anal margin). These two systems have vascular connections under the anal mucosa.
- vascular formations are circumferential but are concentrated in hemorrhoidal "bundles" according to the number of arterial pedicles which supply them. These bundles are usually three in number: anferro-droif, posferro-droop and left lateral bundle. They also have a role of cushioning cushion during rectal evacuation. They maintain their anatomical position (in particular during the evacuation of the stool) thanks to elastic fibers coming from the sphincter apparatus. Thus in the normal state, we do not perceive the presence of hemorrhoids.
- Hemorrhoidal disease is a mild disease and the symptoms are very bothersome. The main symptoms of hemorrhoidal disease are bleeding, pain, and swelling. There are generally four grades of anatomical changes on procfologic examination.
- Grade 3 Frank exteriorization upon defecation or exertion, followed by slow spontaneous reduction or aided by finger pressure.
- Grade 4 permanent externalization (hemorrhoidal prolapse).
- the medical treatment which is based on the regularization of the intestinal transit by treating constipation, on the administration of drugs having a venous tonic effect e ⁇ local topicals (creams and suppositories) e ⁇ the instrumental treatment carried out in the consultation cabin ⁇ ( infrared, elastic ligation ...) are generally no longer effective when there is a significant proportion.
- hemorrhoidal surgery is generally indicated depending on the patient's request. Only 10% to 15% of patients require surgical treatment.
- Hemorrhoidopexy is indicated when the incidence of internal hemorrhoids is symmetrical on the three main bundles or almost circumferential e ⁇ of grade 3. It is ⁇ particularly adapted to patients who must exert efforts during defecation e ⁇ in whom it is often observed on examination carried out with an anoscope, that the prolapse of the hemorrhoids is accompanied by an internal prolapse of the lining of the lower rectum.
- the interest of this ⁇ intervention is ⁇ the maintenance of the integrity of the anal canal and the anal margin with a technique that avoids an operative wound. Longo's intervention is less painful postoperatively and allows rapid resumption of activities.
- Hemorrhoidectomy is a possible intervention in all circumstances. It is necessary when only one or two hemorrhoidal bundles are pathological e ⁇ can be excised with little painful operative consequences. It is used to treat an external hemorrhoidal disease (repeated thrombosis, residual skin marisks or excess). It guarantees ⁇ the result ⁇ in the event of permanently exteriorized hemorrhoids (grade 4). It is most suitable in grade 3 hemorrhoids in the absence of rectal mucosal prolapse e ⁇ when the external hemorrhoidal component is clear.
- Surgical treatments such as above are however relatively heavy, painful and require postoperative monitoring before resuming normal urination.
- such interventions require a work stoppage modulated according to the findings of the first postoperative visit e ⁇ of the type professional activity.
- the average duration of stoppages is ⁇ one to two weeks after hemorrhoidopexy and three to four weeks after hemorrhoidectomy.
- the HEMAPRO TM composition is ⁇ a hemorrhoid cream based on a formula that contains a plant complex formed from goldenrod, lemon and butcher's broom which are ⁇ known for their edema reducing, calming and stimulating properties.
- DIEPHARMEX TM Laboratories have also designed an an ⁇ i-hemorrhoidal gel: MICRO H TM. This gel, packaged in particular in single doses of 5 ml, lines the mucous membranes of the anal canal with a soothing protective gel, promoting natural healing.
- SEDORRHOIDE TM HEMORROIDAL CRISIS rectal cream is an anti-inflammatory and local anesthetic. This medication is recommended in certain anal pathologies accompanied by pain and / or itching, in particular in hemorrhoidal crisis.
- Document EP0391905 describes a topical composition based on the aluminum salt of sucrose octasulfate useful for the prevention and treatment of hemorrhoidal disease in addition to its healing action.
- Document FR3026948 describes a topical cosmetic and / or dermatological composition, in particular useful for preventing or treating hemorrhoidal disease comprising, in a physiologically acceptable carrier, at least an effective amount of potassium salt of synthetic polysulfated oligosaccharide having 1 to 4 units of 'dares.
- the present invention relates to a composition in a form suitable for topical herbal administration, as well as its method of manufacture.
- the invention also relates to such a composition for its use in the treatment or prevention of symptoms in the event of dermatological or gastroenterological conditions, in particular proctological conditions such as hemorrhoidal disease.
- proctological conditions such as hemorrhoidal disease.
- procfological conditions such as hemorrhoidal disease.
- a problem which the present invention proposes to solve consists in particular in developing compositions which are easy and quick to apply, simple to use, and which exhibit improved efficacy (over time, both quantitative and qualitative. ) crazy ⁇ while limiting the impact on the environment.
- the first object of the solution to this problem is a composition in a form suitable for topical administration comprising, in a cosmetically and / or pharmaceutically acceptable vehicle, at least one nettle extract (Urtica), characterized in that that it also comprises a mixture of at least five among the twenty-three following plant extracts:
- Its second object is a process for preparing a composition according to the invention, characterized in that it comprises the following steps of:
- composition according to the invention for its use in the prevention and / or treatment of symptoms in the event of dermatological conditions, in particular human conditions.
- composition according to the invention for the prevention or treatment of the symptoms of hemorrhoidal disease.
- composition which is the subject of the invention makes it possible to increase the effectiveness of the compositions for the treatment or prevention of dermatological or gastroenterological conditions, in particular of proctological conditions such as hemorrhoidal disease.
- composition according to the invention comprising at least one extract of nettle (Urtica) and at least one mixture of at least five other plant extracts, applied topically, presents in particular one or more of the following benefits:
- composition developed by the Applicant is stable and well tolerated.
- compositions according to the invention allow prolonged release of the active component (s). This results in a longer duration of action and a better safety profile.
- an interval when given, it includes the upper and lower bounds of said interval.
- a compound when referring to a compound, it includes any pharmaceutically acceptable form and in particular isomers, salts, solvates and polymorphs. In particular if a compound exhibits optical activity, the referenced compound will include the racemic mixture of the different isomers.
- the subject of the invention is a pharmaceutical or cosmetic composition. It is in a form suitable for topical application, in particular suitable for its place of administration (skin, scalp, hair, etc.), preferably skin lesions or hemorrhoids.
- the composition comprises, in a cosmetically and / or pharmaceutically acceptable vehicle, at least one extract of nettle (Urtica).
- cosmetic and / or pharmaceutically acceptable vehicle denotes a non-toxic support capable of being applied to at least one keratin material of human beings.
- the cosmetic and / or dermatological composition is advantageously a composition for topical application, comprising a cosmetically or dermatologically acceptable medium, that is to say which has a pleasant color, odor and feel and which does not generate unacceptable discomfort. (tingling, tightness, redness), likely to distract consumers from the use of this composition.
- composition according to the invention further comprises a mixture of at least five from the following twenty-three plant extracts:
- composition comprises five of the twenty-two plant extracts listed above, it is preferably the following mixtures:
- the composition according to the invention comprises more than five among the twenty-three plant extracts listed above, preferably ten, twelve, fifteen or twenty plant extracts.
- the composition according to the invention comprises a nettle extract (Urfica) and all the following plant extracts: marigold (Calendula), dandelion (Taraxacum), elderberry (Sambucus), rosemary ( Rosmarinus officinalis), sage (Salvia officinalis), wormwood (Arfemisia absinfhium L.), burdock (Arcfium lappa), thyme (Thymus serpyllum), willow (Salix), planfago (Planfago lanceolafa), l ' sweet flag (Acorus calamus), aloe (Asphodeloideae), blackberry (Morus), grafferon gaillef (Galium aparine L.), yellow gentian (Genfiana lufea), yarrow (Achillea millefolium L.), basil (Ocimum basilicum), glechoma ground ivy (Urfic
- the various extracts are preferentially dispersed in a lipophilic phase composed of oils, fats and / or waxes, of plant, animal, mineral or synthetic origin.
- the vegetable oil is olive oil.
- usable vegetable fats By way of nonlimiting example of usable vegetable fats, mention may in particular be made of shea butter, cocoa butter and mango butter, taken alone or as a mixture. Preferably, the vegetable fat is shea butter.
- cactus carnauba (cactus) wax
- soybean wax soybean wax
- jojoba wax candela (palm) wax
- the vegetable wax is soy wax.
- the animal oil is cod oil.
- animal fat is lard.
- animal waxes which can be used, mention may in particular be made of beeswax or whale white, taken alone or as a mixture.
- the animal wax is beeswax.
- oils By way of nonlimiting example of oils, fats or mineral waxes which can be used, mention may in particular be made of petroleum jelly and paraffin, taken alone or as a mixture.
- oils, fats or synthetic waxes which can be used, mention may in particular be made of silicone oil or silicone wax, fatty esters and fatty alcohols, taken alone or as a mixture.
- the lipophilic phase is preferably an animal fatty phase, more preferably lard.
- the fatty phase represents at least 10% by weight of the total weight of the composition (w / w).
- the fatty phase representing between 10% and 99% by weight of the total weight of the composition (w / w). More preferably, the fatty phase represents between 50% and 90% by weight of the total weight of the composition (w / w). In fact, for such a range of fatty phase proportions, a good compromise is observed between a stable emulsion containing sufficient fatty phase for application in dermatology (in particular for dry skin) and good tissue tolerance.
- a high level of fatty phase is particularly advantageous for dermatological compositions intended for the care of the skin, and in particular for dry skin.
- composition according to the invention may further comprise one or more additives compatible with cosmetic and / or dermatological use.
- these adjuvants must not harm the properties of the composition according to the invention, that is to say in particular the absence of irritability of the skin.
- the pharmaceutical composition according to the invention may contain other additional ingredients such as an adjuvant, an ⁇ i-oxydan ⁇ , a chelating agent, a ⁇ ensio-ac ⁇ if, a foaming agent, a wetting agent, an emulsifying agent, a viscosifian ⁇ , a buffering agent or a preservative, preferably a preservative.
- additional ingredients such as an adjuvant, an ⁇ i-oxydan ⁇ , a chelating agent, a ⁇ ensio-ac ⁇ if, a foaming agent, a wetting agent, an emulsifying agent, a viscosifian ⁇ , a buffering agent or a preservative, preferably a preservative.
- the pharmaceutical composition according to the invention may contain an agent which improves permeation or penetration.
- permeation or penetration enhancer is intended to mean a compound which makes it possible to significantly improve the skin penetration of the active ingredient according to the invention.
- oleic acid By way of illustrative example of an agen ⁇ improving permeation or penetration, we can mention oleic acid, oleic alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acid, dimethylsulfoxide, polar lipids or N-methyl-2-pyrrolidone.
- the pharmaceutical composition according to the invention may contain a hydrotropic agent which disrupts the structure of the stratum corneum e ⁇ thus making it possible to further increase penetration through the surface layer of the skin.
- hydrotropic agen we can mention sodium xylene sulfonate, isopropyl alcohol, and preferably propylene glycol.
- the composition further comprises at least one pharmaceutically active ingredient chosen from soothing agents, agents for promoting healing and / or restructuring of the skin, antiallergic agents, antibacterial agents. , depigmenting agents, moisturizing agents, kerato lytic agents analgesics, anesthetics, analgesics, antibiotics, antifungals, painkillers, an ⁇ i-inflammatory, antiparasitics, antipruritics antiseptics, antivirals , acne drugs, corticosteroids, vasoconstrictors, venotonics and / or a mixture of these.
- soothing agents agents for promoting healing and / or restructuring of the skin
- antiallergic agents antibacterial agents.
- depigmenting agents moisturizing agents
- kerato lytic agents analgesics, anesthetics, analgesics, antibiotics, antifungals, painkillers, an ⁇ i-inflammatory, antiparasitics, antipruritics antiseptics, antivirals , acne
- acetaminophen fluocinolone acetonide, acetylsalicylic acid, acitretin, clavulanic acid, azelaic acid, acyclovir, adapalene, alclometasone, alpha-tocopherol, amcinonide, amorolfine, amphotericin B, tetracycline, peroxide benzoyl, betamethasone, calcipotriol, calcitriol, ciclopirox, clindamycin, codeine, crisaborole, clobetasol, crotamiton, cyproheptadine, dapsone, desonide, diosmine, dicniflifenluolac, , dioxyanthranol, econazole, efinaconazole, erythro
- compositions according to the invention can be provided in all the galenic forms normally used by the unsuspecting man.
- compositions according to the invention are intended for topical administration and are provided in the form of a solution, of a dispersion, of an emulsion of liquid or semi-liquid consistency, of a suspension. , an aqueous or lipophilic gel, a microemulsion, a microcapsule, a vesicular dispersion, a dressing or an impregnated compression article.
- composition according to the invention is in the form of an ointment.
- composition is in the form of an ointment comprising:
- a lipophilic phase comprising all the extracts of the following plants: marigold (Calendula), dandelion (Taraxacum), elderberry (Sambucus), rosemary (Rosmarinus officinalis), sage (Salvia officinalis), wormwood (Artemisia absinthium L.), burdock (Arctium lappa), wild thyme (Thymus serpyllum), willow (Salix), plantago (Plantago lanceolata), sweet flag (Acorus calamus), aloe (Asphodeloideae), blackberry (Morus), nettle (Urtica), gaille ⁇ gratteron (Galium aparine) L.), yellow gentian (Gentiana lutea), yarrow (Achillea millefolium L.), basil (Ocimum basilicum), ground ivy glechoma (Glechoma hederacea),
- a subject of the invention is also a process for preparing a composition according to one of the preceding claims.
- the preparation process comprises the following steps of:
- the effective amounts of usable plants can be adjusted depending on the end use of the product.
- the term “effective amount” means an amount sufficient to obtain the expected effect.
- the amount of plant or plant extract incorporated into the liquid lipophilic phase is between: - 0.1% e ⁇ 30%, preferably between 5% and 25% and more preferably still between 10% and 20% for nettle;
- composition which is the subject of the invention is particularly indicated for its use in the prevention and / or treatment of dermatological conditions, in particular human conditions.
- the pharmaceutical composition which is the subject of the invention is suitable for use in the prevention and / or treatment of dermatological conditions, in particular human conditions.
- dermatological conditions linked to a keratinization disorder relating to differentiation and cell proliferation in particular to treat common acnes, comedones, polymorphs, rosacea, nodulocystic acnes, conglobata, senile acnes, secondary acnes such as sun acne, medicated or occupational;
- keratinization disorders in particular ichthyosis, ichthyosiform states, lamellar ichthyosis, Darrier's disease, palmoplantar keratoderma, leukoplakia, pityriasis rubra pilaris and leukoplasiform states, cutaneous or mucous (buccal) lichen ;
- any condition linked to benign dermal or epidermal proliferation whether or not of viral origin such as common warts, flat warts, molluscum contagiosum and verruciform epidermodysplasia, oral or florid papillomatosis;
- dermatological disorders such as immune dermatoses such as lupus erythematosus, bullous immune diseases and collagen diseases such as scleroderma;
- the invention relates to a pharmaceutical composition according to the invention for its use as a medicament in the treatment of dermatological conditions, in particular human, as defined above.
- composition which is the subject of the invention is particularly indicated for its use in the prevention and / or treatment of gastroenterological conditions, in particular human conditions, particularly proctological conditions such as the prevention or treatment of hemorrhoidal disease.
- prevention or treatment is meant both any action on the symptoms of hemorrhoids, that is to say concerning the aesthetic appearance of said hemorrhoids as any action on the cause, that is to say any action. on the longitudinal muscles of the rectum forming the ligament of Parks and / or on the opening of arteriovenous shunts, but also any action on the consequences of said hemorrhoids, namely, the scars resulting from said hemorrhoids.
- the composition is also suitable for relieving burns, helping healing, relieving hemorrhoidal crises and has an anti-inflammatory effect.
- Example 1 List of the various plants or parts of plants which can be used for the manufacture of a composition according to the invention: The various ingredients listed below are advantageously used in amounts for the preparation of approximately 5 kg of finished product:
- Marigold or officinal marigold fCalendula including Calendula officinalisl
- composition according to the invention which is advantageously an ointment
- 200 g of fresh marigold leaves are advantageously used. You can replace fresh marigold leaves with dried marigold leaves. Marigold is particularly useful for the treatment of wounds and cuts.
- Dandelion is particularly useful for the treatment of wounds and cuts and promotes good breathing.
- the preparation of the ointment according to the invention approximately 200 g of fresh, uncompacted elder flowers are advantageously used, as well as approximately 50 g of fine (green and soft) elderberry bark.
- Elder flowers are particularly useful for treating wounds and healing the skin.
- Sage is especially useful for the lungs, breathing, and treating inflammation.
- burdock leaves are advantageously used. You can replace the fresh burdock leaves with dried burdock leaves. It is therefore preferable to use three times the amount. Burdock leaves are particularly useful for treating joint injuries. For the preparation of the ointment according to the invention, it is also recommended to include two fresh burdock roots of medium size, obtained from young and finely chopped plants. Burdock roots are particularly useful for the rapid healing of wounds.
- the preparation of the ointment according to the invention advantageously about 40 g to 50 g of fresh thyme leaves are used. You can replace fresh thyme leaves with dried thyme leaves. It is then preferable to use twice the amount.
- Plantaao or lanceolate plantain Plantaao lanceolata
- approximately 50 g to 100 g of young, juicy and fresh leaves are advantageously used, ie approximately 40 leaves of plantago, more preferably a mixture of male and female plants. You can replace fresh plantago leaves with dried plantago leaves. It is then preferable to use twice the amount. Plantago leaves are particularly useful for the treatment of many conditions, especially ear infections and inflammation.
- the ointment according to the invention use is advantageously made of approximately 150 g to 200 g of roots (approximately two roots) of fresh fragrant Acore, finely chopped and well cleaned.
- the roots of Core son ⁇ especially useful for the treatment of many ailments.
- the roots are generally available year round.
- approximately 20 to 30 fresh mulberry leaves are advantageously used, ie approximately 30 to 40 g. You can replace the fresh mulberry leaves with dried mulberry / bramble leaves. It is then preferable to use twice the amount.
- the preparation of the ointment according to the invention advantageously about 1 kg of aerial parts of fresh nettles is used. You can replace fresh nettles with dried nettles. It is then preferable to use twice the amount.
- the aerial parts of nettle are the basis of the preparation.
- Gaillet aratteron (Galium aparine L.)
- cleavers For the preparation of the ointment according to the invention, advantageously about two long branches of cleavers, so about 60g, roughly chopped are used. It is preferable not to use wood but rather soft branches.
- the branches of cleavers are particularly useful for the treatment of many skin conditions. It is possible but difficult to use dried branches. If necessary, replace fresh branches with dried ones. It is then preferable to use twice the amount.
- the ointment according to the invention approximately 200 g of clean, fresh roots of yellow gentian, approximately 1 year old, are advantageously used.
- the roots are preferably finely chopped and fresh.
- the roots of yellow gentian are particularly useful for the treatment of many ailments. They have in particular a protective effect on the blood vessels, the liver and allow the cleansing of the organism. They also have an antiseptic effect. 17.
- the preparation of the ointment according to the invention approximately 20 g of angelica flowers and / or roots are advantageously used.
- the addition of angelica in the preparation is optional.
- yarrow flowers For the preparation of the ointment according to the invention, approximately 300 g of fresh yarrow flowers are advantageously used. You can replace fresh yarrow flowers with dried yarrow flowers. It is then preferable to use twice the amount. Yarrow leaves are particularly useful for the treatment of wounds and lung diseases.
- Sheets are generally available year round.
- glechoma For the preparation of the ointment according to the invention, approximately 20g to 30g of fresh glechoma are advantageously used, in pieces of about 15 cm from the top, with a flower, chopped into pieces. It is possible to replace fresh glechoma with dried terrestrial glechoma. It is then preferable to use twice the amount.
- the preparation of the ointment according to the invention advantageously used approximately 150 g of fresh roots of comfrey, unpeeled, well washed, cut into small pieces.
- the fresh roots of comfrey are particularly useful for bone strengthening.
- ivy leaves For the preparation of the ointment according to the invention, approximately 30 g of fresh ivy leaves are advantageously used, ie approximately 20 small young leaves.
- Example 2 Process for manufacturing a composition according to the invention in a lard base
- the basis of the composition includes pork fat (lard) and nettles.
- the different preparation steps are detailed below:
- composition based on plant extracts according to the invention was tested on a panel of three people exhibiting symptoms of hemorrhoidal disease. These symptoms include itching, burning and irritation, and hemorrhoidal episodes. After using the composition based on plant extracts, these different people observed a marked decrease in the symptoms associated with hemorrhoidal disease and an improvement in their comfort.
- the main effects observed are, in particular, soothing during itching, soothing during burns, aid in healing and soothing during hemorrhoidal episodes.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2000515A FR3106276A1 (fr) | 2020-01-20 | 2020-01-20 | Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associé |
PCT/EP2021/050982 WO2021148366A1 (fr) | 2020-01-20 | 2021-01-19 | Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associé |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4093418A1 true EP4093418A1 (fr) | 2022-11-30 |
Family
ID=70008905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21701269.9A Withdrawn EP4093418A1 (fr) | 2020-01-20 | 2021-01-19 | Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associé |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230035038A1 (fr) |
EP (1) | EP4093418A1 (fr) |
CN (1) | CN115361964A (fr) |
FR (1) | FR3106276A1 (fr) |
WO (1) | WO2021148366A1 (fr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4945084A (en) | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
RU2089213C1 (ru) * | 1995-12-21 | 1997-09-10 | Индивидуальное частное научно-производственное предприятие "Градиент" | Средство для фитокоррекции |
US7195781B2 (en) * | 2003-04-21 | 2007-03-27 | Bronhilda Miketin | Method for treatment of skin disorders |
PL2022504T3 (pl) * | 2007-08-08 | 2013-03-29 | Kuecuekay Feyyaz | Maść do leczenia hemoroidów |
RS20100392A3 (en) * | 2010-09-06 | 2012-12-31 | Pavlov, Aleksandar | PROCEDURE FOR OBTAINING A HERBAL PREPARATION BASED ON AN EXTRACT OF A HERBAL MIXTURE FOR APPLICATION TO THE SKIN AND A HERBAL PREPARATION OBTAINED BY THIS PROCEDURE |
RO126182B1 (ro) * | 2010-09-10 | 2014-01-30 | Favisan S.R.L. | Supozitoare destinate sănătăţii aparatului urogenital feminin şi masculin |
FR3026948A1 (fr) | 2014-10-09 | 2016-04-15 | Urgo Lab | Composition cosmetique et/ou dermatologique pour la prevention et le traitement des hemorroides |
-
2020
- 2020-01-20 FR FR2000515A patent/FR3106276A1/fr active Pending
-
2021
- 2021-01-19 EP EP21701269.9A patent/EP4093418A1/fr not_active Withdrawn
- 2021-01-19 WO PCT/EP2021/050982 patent/WO2021148366A1/fr unknown
- 2021-01-19 US US17/759,122 patent/US20230035038A1/en active Pending
- 2021-01-19 CN CN202180009710.9A patent/CN115361964A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230035038A1 (en) | 2023-02-02 |
CN115361964A (zh) | 2022-11-18 |
WO2021148366A1 (fr) | 2021-07-29 |
FR3106276A1 (fr) | 2021-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2694021B1 (fr) | Composition cicatrisante pour application topique | |
CH654482A5 (fr) | Composition therapeutique de dimethylsulfoxyde. | |
EP1641463A1 (fr) | Compositions sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase huileuse non volatile | |
EP3439676B1 (fr) | Composition topique d'huile de poisson | |
EP3393488A1 (fr) | Composition comprenant un extrait d'ambora et un extrait de thé vert pour le traitement du psoriasis, de la dermatite atopique, de l'urticaire chroniques, du prurit resistant aux antihistaminiques et du prurit senile | |
US20140271920A1 (en) | Skin ointment formulation | |
EP2343038B1 (fr) | Compositions dermatologiques contenant une association de lipides peroxydés et de zinc et leurs utilisations notamment dans le traitement de l'herpès | |
CA2252633A1 (fr) | Compositions cosmetiques et/ou pharmaceutiques et/ou dermatologiques | |
EP4093418A1 (fr) | Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associé | |
EP2692332B1 (fr) | Composition pour le traitement de cal, cors et psoriasis | |
EP2104496A2 (fr) | Utilisation du nepafenac ou ses derives pour le traitement de la rosacée, l'acné, le psoriasis et la dermatite atopique | |
WO2000074668A1 (fr) | Composition non solide pour application locale | |
US20190365735A1 (en) | Compositions and methods for treating varicose veins | |
US10071052B2 (en) | Method for the prevention and treatment of acne | |
KR20240062990A (ko) | 부상 및/또는 피부 병태의 치료를 위한 조성물 및 방법 | |
KR20040043596A (ko) | 셀룰로스를 유효성분으로 함유하는 항각질 조성물 | |
WO2023046892A1 (fr) | Solution aqueuse a base de syzygium aromaticum, procede de preparation et utilisations associees | |
WO2019008301A2 (fr) | Compositions végétales pour application cutanée | |
WO2023247796A1 (fr) | Composition de soins de la peau | |
EP2165698A1 (fr) | Composition cosmétique destinée au soin de peaux agressées | |
FR2773077A1 (fr) | Composition non solide pour application locale | |
EP2282732A2 (fr) | Utilisation d'un extrait d'huile d'olive pour le controle du vieillissement cutane | |
CA2402644A1 (fr) | Methode, composition et son utilisation pour traiter et empecher la perte de cheveux | |
WO2007125262A1 (fr) | Utilisation d'une composition dermatologique comprenant une association d'hydroquinone, d'acétonide de fluocinolone et de trétinoine, destinée au traitement de l'hyperpigmentation des cicatrices pathologiques | |
FR2912054A1 (fr) | Composition cosmetique comprenant une association de trois formes de vitamine c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220623 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230310 |